RLMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Relmada Therapeutics Inc (RLMD) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows positive momentum, strong insider buying, promising clinical data for its lead candidate NDV-01, and favorable analyst ratings with significant upside potential. Despite financial challenges, the company's pipeline and market opportunity in bladder cancer provide a compelling growth story.
The technical indicators are bullish. The MACD is positive and contracting, the RSI is neutral at 60.164, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 6.017, with resistance levels at 7.216 and 7.958, suggesting room for upward movement.
Promising clinical data for NDV-01, with a 95% complete response rate in Phase 2 trials and confirmed Phase 3 pathways.
Strong insider buying, with a 1133.44% increase in the last month.
Favorable analyst ratings with upside price targets ranging from $8 to $14.
Financial pressure highlighted by a net loss of $19.9 million in Q4 2025 and declining EPS.
Challenges in profitability with missed EPS expectations in Q4 2025.
In Q4 2025, the company reported a net loss of $19.9 million, a 6.49% YoY improvement. However, EPS dropped by 46.77% YoY to -$0.33, indicating profitability challenges. The company has a cash balance of $93 million, which provides some runway for its clinical programs.
Analysts are optimistic about RLMD, with recent ratings including Buy from Lucid Capital ($14 price target), Outperform from Leerink ($8 price target), and Buy from Jefferies ($9 price target). Analysts highlight the potential of NDV-01 in bladder cancer and its addressable market of $2.3 billion in peak sales.
